Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-19 pm EDT 5-day change 1st Jan Change
42.64 USD +0.59% Intraday chart for Bristol-Myers Squibb Company +5.39% -16.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bristol-Myers Gets EMA Validation For Opdivo Combination Application to Treat Liver cancer MT
Bristol Myers Gets EMA Review of Opdivo/Yervoy Combo in Liver Cancer DJ
Bristol Myers: application validated by the EMA in liver cancer CF
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo Plus Yervoy for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma CI
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative MT
Earnings reports take center stage as tech stocks tumble Our Logo
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $45 From $67 MT
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly... Our Logo
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained MT
Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 MT
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Bristol Myers: accelerated approval in colorectal cancer CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval MT
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.64 USD
Average target price
51.69 USD
Spread / Average Target
+21.23%
Consensus
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval